Inside Johnson & Johnson's Two-Headed Growth Engine

J&J's pharmaceutical segment generated approximately $56 billion in 2025 revenue, anchored by immunology (Stelara, Tremfya), oncology (Darzalex, Erleada, Carvykti), and neuroscience (Spravato). The segment's operating margin exceeds 35%, making it the primary profit driver.

The elephant in the room is Stelara. The blockbuster immunology drug generated roughly $20 billion at peak and began facing biosimilar competition in early 2025. Revenue erosion has been slower than feared — the transition to Tremfya as the next-generation immunology backbone has been remarkably smooth.

Tremfya, approved for psoriasis and psoriatic arthritis with inflammatory bowel disease indications in late-stage trials, has the potential to become a $10-12 billion peak revenue product. The clinical data in ulcerative colitis was, frankly, best-in-class — 67% clinical remission rates that exceeded both Stelara and competing IL-23 inhibitors.

The Research Desk has covered enough biosimilar transitions to know the pattern: the first 12 months see 20-30% erosion, then the rate slows as physicians who prefer the originator product stick with it. J&J's internal projections suggest Stelara will still generate $8-10 billion in 2027, buying Tremfya time to scale.

J&J's MedTech segment — orthopaedics, surgery, vision, and cardiovascular — generated approximately $31 billion in 2025 revenue. The segment often gets overlooked because pharmaceutical margins are higher, but MedTech provides something pharma can't: recurring procedure-based revenue with no patent cliff risk.

The Abiomed acquisition (heart pumps) and the Shockwave Medical acquisition (intravascular lithotripsy) have strengthened the cardiovascular portfolio considerably. Shockwave's technology, which uses sonic pressure waves to break calcified arterial plaque, addresses a $7 billion market growing at 15% annually.

Robotic surgery is another growth vector. J&J's Ottava surgical robot — expected to launch in 2027 — targets the same market that Intuitive Surgical dominates with the da Vinci system. While Intuitive has a massive installed base advantage, J&J's strategy of bundling Ottava with its existing surgical instruments and orthopaedic implants creates a differentiated go-to-market approach.

MedTech margins are expanding as higher-growth, higher-margin acquisitions scale and legacy orthopaedic product lines are rationalised. We expect segment operating margins to expand from 26% to 29% by 2028.

J&J has 14 compounds in Phase 3 or registration across immunology, oncology, and neuroscience. The most promising beyond Tremfya include:

Nipocalimab — an anti-FcRn antibody targeting generalised myasthenia gravis and haemolytic disease of the fetus. Peak sales estimates range from $3-5 billion. Phase 3 data expected mid-2026.

Carvykti — the BCMA-directed CAR-T therapy for multiple myeloma. Already approved, but the move to earlier-line treatment could expand the addressable market from $5 billion to $15 billion.

Spravato — the esketamine nasal spray for treatment-resistant depression has been quietly becoming a blockbuster, with 2025 revenue approaching $2 billion. Label expansion into major depressive disorder with suicidal ideation opens additional market.

The combined peak sales potential of the late-stage pipeline exceeds $30 billion. Even applying a typical 50% probability-of-success adjustment, that's $15 billion in risk-adjusted incremental revenue — more than enough to offset the Stelara erosion.